ROS Therapeutics Holding ApS: Financial statements 2024
CVR: 39507056
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ROS Therapeutics Holding ApS (CVR 39507056) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -12,875 and a net result of DKK -14,342 compared with DKK -13,845 the year before. Equity in the 2024 report amounted to DKK -256,054. The company had 1 employee in the financial year.
- Gross Profit
- DKK -12,875
- Profit/Loss
- DKK -14,342
- Equity
- DKK -256,054
- Total Assets
- DKK 18,514
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -13K | -14K | -256K | 1 |
| 2023 | - | -13K | -14K | -243K | 1 |
| 2022 | - | -13K | -14K | -229K | 1 |
| 2021 | - | -13K | -4.3M | -225K | 1 |
| 2020 | - | -13K | 4M | 4.1M | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ROS Therapeutics Holding ApS has published its annual report for 2023. Gross profit came to DKK -12,500, and the net result was DKK -13,845.
About ROS Therapeutics Holding ApS
ROS Therapeutics Holding ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Hanne Damgaard Jensen. The company is owned by SPORCON LIFESCIENCE ADVISORS ApS and HDJ & LEJ Invest ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -10,750 and a net result of DKK -26,512 compared with DKK -14,342 the year before. Equity in the 2025 report amounted to DKK -116,804.
